EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 39 / Numéro 4 (Avril 2023) Med Sci (Paris), 39 4 (2023) 359-369 Références
Open Access
Numéro
Med Sci (Paris)
Volume 39, Numéro 4, Avril 2023
Page(s) 359 - 369
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2023053
Publié en ligne 24 avril 2023
  1. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; ehac237. [Google Scholar]
  2. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2022; 2200879. [Google Scholar]
  3. Hoeper MM, Humbert M. The new haemodynamic definition of pulmonary hypertension: evidence prevails, finally!. Eur Respir J 2019 ; 53 : 1900038. [CrossRef] [PubMed] [Google Scholar]
  4. Maron BA, Brittain EL, Hess E, et al. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir Med 2020; 8 : 873–84. [CrossRef] [PubMed] [Google Scholar]
  5. Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J 2019 ; 53 : 1801887. [CrossRef] [PubMed] [Google Scholar]
  6. Lau EMT, Giannoulatou E, Celermajer DS, et al. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol 2017 ; 14 : 603–614. [CrossRef] [PubMed] [Google Scholar]
  7. Weatherald J, Chaumais M-C, Savale L, et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. Eur Respir J 2017 ; 50 : 1700217. [CrossRef] [PubMed] [Google Scholar]
  8. Savale L, Chaumais M-C, Cottin V, et al. Pulmonary hypertension associated with benfluorex exposure. Eur Respir J 2012 ; 40 : 1164–1172. [CrossRef] [PubMed] [Google Scholar]
  9. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996 ; 335 : 609–616. [CrossRef] [PubMed] [Google Scholar]
  10. Montani D, Lau EM, Descatha A, et al. Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. Eur Respir J 2015 ; 46 : 1721–1731. [CrossRef] [PubMed] [Google Scholar]
  11. Montani D, Lau EM, Dorfmüller P, et al. Pulmonary veno-occlusive disease. Eur Respir J 2016 ; 47 : 1518–1534. [CrossRef] [PubMed] [Google Scholar]
  12. Perros F, Humbert M, Dorfmüller P. Smouldering fire or conflagration? An illustrated update on the concept of inflammation in pulmonary arterial hypertension. Eur Respir Rev 2021; 30 : 210161. [CrossRef] [PubMed] [Google Scholar]
  13. Ranchoux B, Antigny F, Rucker-Martin C, et al. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation 2015 ; 131 : 1006–1018. [CrossRef] [PubMed] [Google Scholar]
  14. Ranchoux B, Günther S, Quarck R, et al. Chemotherapy-induced pulmonary hypertension: role of alkylating agents. Am J Pathol 2015 ; 185 : 356–371. [CrossRef] [PubMed] [Google Scholar]
  15. Perros F, Günther S, Ranchoux B, et al. Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models. Circulation 2015 ; 132 : 834–847. [CrossRef] [PubMed] [Google Scholar]
  16. Caliez J, Riou M, Manaud G, et al. Trichloroethylene increases pulmonary endothelial permeability: implication for pulmonary veno-occlusive disease. Pulm Circ 2020; 10 : 2045894020907884. [CrossRef] [Google Scholar]
  17. Nossent EJ, Antigny F, Montani D, et al. Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. J Heart Lung Transplant 2018 ; 37 : 647–655. [CrossRef] [PubMed] [Google Scholar]
  18. Manaud G, Nossent EJ, Lambert M, et al. Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease. Am J Respir Cell Mol Biol 2020; 63 : 118–31. [CrossRef] [PubMed] [Google Scholar]
  19. Santos-Ribeiro D, Godinas L, Pilette C, et al. The integrated stress response system in cardiovascular disease. Drug Discov Today 2018 ; 23 : 920–929. [CrossRef] [PubMed] [Google Scholar]
  20. Valuparampil Varghese M, James J, Eccles CA, et al. Inhibition of Anaplerosis Attenuated Vascular Proliferation in Pulmonary Arterial Hypertension. J Clin Med 2020; 9 : E443. [CrossRef] [PubMed] [Google Scholar]
  21. Perros F, Humbert M, Cohen-Kaminsky S Hypertension artérielle pulmonaire. Un parfum d’auto-immunité. Med Sci (Paris) 2013 ; 29 : 607–616. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  22. Perros F, Dorfmüller P, Souza R, et al. Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J 2007 ; 29 : 462–468. [CrossRef] [PubMed] [Google Scholar]
  23. Hautefort A, Girerd B, Montani D, et al. T-helper 17 cell polarization in pulmonary arterial hypertension. Chest 2015 ; 147 : 1610–1620. [CrossRef] [PubMed] [Google Scholar]
  24. Perros F, Dorfmüller P, Montani D, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2012 ; 185 : 311–321. [CrossRef] [PubMed] [Google Scholar]
  25. Koudstaal T, van Hulst JAC, Das T, et al. DNGR1-Cre-mediated Deletion of Tnfaip3/A20 in Conventional Dendritic Cells Induces Pulmonary Hypertension in Mice. Am J Respir Cell Mol Biol 2020; 63 : 665–80. [CrossRef] [PubMed] [Google Scholar]
  26. van Uden D, Koudstaal T, van Hulst JAC, et al. Central Role of Dendritic Cells in Pulmonary Arterial Hypertension in Human and Mice. Int J Mol Sci 2021; 22 : 1756. [CrossRef] [PubMed] [Google Scholar]
  27. Hautefort A, Mendes-Ferreira P, Sabourin J, et al. Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension. Circulation 2019 ; 139 : 932–948. [CrossRef] [PubMed] [Google Scholar]
  28. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005 ; 111 : 3105–3111. [CrossRef] [PubMed] [Google Scholar]
  29. Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 2010 ; 31 : 1898–1907. [CrossRef] [PubMed] [Google Scholar]
  30. Clozel M, Maresta A, Humbert M. Endothelin receptor antagonists. Handb Exp Pharmacol 2013 ; 218 : 199–227. [CrossRef] [PubMed] [Google Scholar]
  31. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005 ; 353 : 2148–2157. [CrossRef] [PubMed] [Google Scholar]
  32. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009 ; 119 : 2894–2903. [CrossRef] [PubMed] [Google Scholar]
  33. Ghofrani H-A, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013 ; 369 : 330–340. [CrossRef] [PubMed] [Google Scholar]
  34. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990 ; 112 : 485–491. [CrossRef] [PubMed] [Google Scholar]
  35. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002 ; 347 : 322–329. [CrossRef] [PubMed] [Google Scholar]
  36. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002 ; 165 : 800–804. [CrossRef] [PubMed] [Google Scholar]
  37. Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012 ; 40 : 874–880. [CrossRef] [PubMed] [Google Scholar]
  38. Yusen RD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report–2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant 2015 ; 34 : 1264–1277. [CrossRef] [PubMed] [Google Scholar]
  39. Long L, Ormiston ML, Yang X, et al. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat Med 2015 ; 21 : 777–785. [CrossRef] [PubMed] [Google Scholar]
  40. Morrell NW, Aldred MA, Chung WK, et al. Genetics and genomics of pulmonary arterial hypertension. Eur Respir J 2019 ; 53 : 1801899. [CrossRef] [PubMed] [Google Scholar]
  41. Humbert M, Montani D, Savale L, et al. Cibler les ligands du récepteur de l’activine de type IIA pour traiter l’hypertension artérielle pulmonaire. Med Sci (Paris) 2021; 37 : 839–43. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  42. Guignabert C, Humbert M. Targeting transforming growth factor-β receptors in pulmonary hypertension. Eur Respir J 2021; 57 : 2002341. [CrossRef] [PubMed] [Google Scholar]
  43. Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2021; 384 : 1204–15. [CrossRef] [PubMed] [Google Scholar]
  44. Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. Eur Respir J 2023; 61 : 2201347. [CrossRef] [PubMed] [Google Scholar]
  45. Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3 Trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med 2023 Mar 6. doi:10.1056/NEJMoa2213558. [PubMed] [Google Scholar]
  46. Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013 ; 127 : 1128–1138. [CrossRef] [PubMed] [Google Scholar]
  47. Galkin A, Sitapara R, Clemons B, et al. Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension. Eur Respir J 2022; 60 : 2102356. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.